Threat∑DerivedConfidence: LowSnapshot Nov 8, 2026 · assessed Nov 8, 2026
Manufacturer concentration of current shortage postings: reporting-share HHI 593 over 940 entries
An HHI computed over manufacturer shares of Current shortage postings. This is a reporting-share concentration, not a market-share HHI, and says nothing about who supplies the market.
Why this matters
Illustrates the HHI method and its denominator discipline on a dataset where the denominator is actually complete; a market HHI needs trade or sales shares.
What the evidence says
Top manufacturers by Current postings: Fresenius Kabi USA, LLC (146), Hospira, Inc. (129), Hikma Pharmaceuticals USA Inc. (76), Baxter Healthcare Corporation (45), Eugia US LLC (42).
Denominator: 940 Current entries with a manufacturer name.
Fresenius Kabi USA, LLC146
Hospira, Inc.129
Hikma Pharmaceuticals USA …76
Baxter Healthcare Corporat…45
Eugia US LLC42
Somerset Therapeutics, LLC25
Current shortage postings by manufacturer (top 6).
Category
count
Fresenius Kabi USA, LLC
146
Hospira, Inc.
129
Hikma Pharmaceuticals USA …
76
Baxter Healthcare Corporat…
45
Eugia US LLC
42
Somerset Therapeutics, LLC
25
Current shortage postings by manufacturer (top 6).
What remains uncertain
Posting counts are not market shares; a manufacturer with many package entries is over-represented.
No private supplier relationship is inferred.
Scoring and methodology
No score family applies to this derived count; the method is the formula stated in the evidence section.
Timeline
retrieved
Retrieved · Nov 8, 2026
assessed
Assessed · Nov 8, 2026
Event, published, retrieved, and assessed times are stored separately and never conflated.
Explore the relationships
Related insights are linked only through shared sources or mapped topics. Open the evidence graph.
What to investigate next
Replace with trade-flow or sales-share denominators when a licensed source is available.
Composition of shortage_reason among Current openFDA drug shortage records. Reasons are manufacturer-reported categories; many entries state no reason.
Not stated678
Other164
Demand increase for the drug126
Shortage of an active ingredient61
Discontinuation of the manufacture of the drug46
Stated shortage reasons among Current entries.
Category
count
Not stated
678
Other
164
Demand increase for the drug
126
Shortage of an active ingredient
61
Discontinuation of the manufacture of the drug
46
Stated shortage reasons among Current entries.
Confidence: Moderate1 sourceSupplyFragility: not scored